FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Gene Ther / A pilot study to determine the optimal dose of scAAVIL-1ra i...
Gene therapy2023; doi: 10.1038/s41434-023-00420-2

A pilot study to determine the optimal dose of scAAVIL-1ra in a large animal model of post-traumatic osteoarthritis.

Abstract: Gene therapy approaches using adeno-associated viral vectors have been successfully tested in the equine post-traumatic osteoarthritis (PTOA) model. Owing to differences in the levels of transgene expression and adverse tissue reactions observed in published studies, we sought to identify a safe therapeutic dose of scAAVIL-1ra in an inflamed and injured joint that would result in improved functional outcomes without any adverse events. scAAVIL-1ra was delivered intra-articularly over a 100-fold range, and horses were evaluated throughout and at the end of the 10-week study. A dose-related increase in IL-1ra levels with a decrease in PGE levels was observed, with the peak IL-1ra concentration being observed 7 days post-treatment in all groups. Perivascular infiltration with mononuclear cells was observed within the synovial membrane of the joint treated with the highest viral dose of 5 × 10 vg, but this was absent in the lower-dosed joints. The second-highest dose of scAAVeqIL-1ra 5 × 10 vg demonstrated elevated IL-1ra levels without any cellular response in the synovium. Taken together, the data suggest that the 10-fold lower dose of 5 × 10vg scAAVIL-1ra would be a safe therapeutic dose in an equine model of PTOA.
© 2023. The Author(s).
Get Full Text
Publication Date: 2023-09-11 PubMed ID: 37696981PubMed Central: 3626203DOI: 10.1038/s41434-023-00420-2Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article investigates the use of gene therapy to treat post-traumatic osteoarthritis in horses. The researchers aim to identify a safe dosage of a specific gene therapy treatment that results in improved outcomes without causing any adverse reactions.

Summary of Research Methodology

  • The researchers used an adeno-associated viral vectors gene therapy approach which has previously been successful in treating post-traumatic osteoarthritis (PTOA) in equine models.
  • The specific treatment, known as scAAVIL-1ra, was delivered intra-articularly, or within the joint, over a 100-fold range.
  • Horses were evaluated at intervals and at the end of a 10-week study period to determine the effects of varying dosages of the treatment.

Results of the Study

  • The study findings indicated a dose-related increase in IL-1ra levels. This type of protein is directly related to anti-inflammation. With a decrease in PGE levels, which are associated with inflammation in traumatic injuries, it is inferred that the treatment has potential anti-inflammatory effects.
  • Peak IL-1ra concentration was observed 7 days following treatment in all groups, suggesting that this could be the optimal time for measuring results.
  • However, an adverse tissue reaction was observed in the form of perivascular infiltration with mononuclear cells, specifically in the synovial membrane of the joint treated with the highest viral dose (5 × 10 vg).
  • This adverse reaction was not observed in joints treated with lower doses.

Conclusion

  • The second-highest dose of 5 × 10 vg demonstrated elevated IL-1ra levels without provoking any adverse cellular reaction in the synovium, suggesting that it might be a more appropriate dosage.
  • Overall, the data suggest a therapeutic dose 10-fold lower than the highest dose investigated (5 × 10vg) would be safe for use in an equine model of PTOA.
  • This research opens a door to further explore the potential of gene therapy in managing and treating osteoarthritis in large animals such as horses.

Cite This Article

APA
Thampi P, Seabaugh KA, Pezzanite LM, Chu CR, Phillips JN, Grieger JC, McIlwraith CW, Samulski RJ, Goodrich LR. (2023). A pilot study to determine the optimal dose of scAAVIL-1ra in a large animal model of post-traumatic osteoarthritis. Gene Ther. https://doi.org/10.1038/s41434-023-00420-2

Publication

Gene therapy
ISSN: 1476-5462
NlmUniqueID: 9421525
Country: England
Language: English

Researcher Affiliations

Thampi, P
  • Orthopaedic Research Center, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, CO, USA.
Seabaugh, K A
  • Orthopaedic Research Center, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, CO, USA.
Pezzanite, L M
  • Orthopaedic Research Center, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, CO, USA.
Chu, C R
  • Department of Orthopaedic Surgery, Stanford University, Stanford, CA, USA.
  • Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA, USA.
Phillips, J N
  • Orthopaedic Research Center, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, CO, USA.
Grieger, J C
  • Gene Therapy Center, University of North Carolina, Chapel Hill, NC, USA.
McIlwraith, C W
  • Orthopaedic Research Center, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, CO, USA.
Samulski, R J
  • Gene Therapy Center, University of North Carolina, Chapel Hill, NC, USA.
Goodrich, L R
  • Orthopaedic Research Center, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, CO, USA. laurie.goodrich@colostate.edu.

Grant Funding

  • 62326995-156499 / U.S. Department of Defense (United States Department of Defense)
  • W81XWH1810572 / U.S. Department of Defense (United States Department of Defense)
  • W81XWH1810572 / U.S. Department of Defense (United States Department of Defense)
  • 62326995-156499 / U.S. Department of Defense (United States Department of Defense)
  • W81XWH1810572 / U.S. Department of Defense (United States Department of Defense)
  • 62326995-156499 / U.S. Department of Defense (United States Department of Defense)
  • W81XWH1810572 / U.S. Department of Defense (United States Department of Defense)
  • W81XWH1810572 / U.S. Department of Defense (United States Department of Defense)
  • W81XWH1810572 / U.S. Department of Defense (United States Department of Defense)
  • 62326995-156499 / U.S. Department of Defense (United States Department of Defense)
  • W81XWH1810572 / U.S. Department of Defense (United States Department of Defense)

References

This article includes 58 references
  1. Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA. Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data. Arthritis Rheum 2009;60:3546–53.
    pubmed: 19950287doi: 10.1002/art.24984google scholar: lookup
  2. Cisternas MG, Murphy L, Sacks JJ, Solomon DH, Pasta DJ, Helmick CG. Alternative methods for defining osteoarthritis and the impact on estimating prevalence in a US population‐based survey. Arthritis Care Res 2016;68:574–80.
    doi: 10.1002/acr.22721google scholar: lookup
  3. Dyson SJ, Ross MW. Diagnosis and Management of Lameness in the Horse. WB Saunders Company; 2011.
  4. Goodrich LR, Nixon AJ. Medical treatment of osteoarthritis in the horse - a review. Vet J 2006;171:51–69.
    pubmed: 16427582doi: 10.1016/j.tvjl.2004.07.008google scholar: lookup
  5. McIlwraith CW, Frisbie DD, Kawcak CE. The horse as a model of naturally occurring osteoarthritis. Bone Joint Res 2012;1:297–309.
    pubmed: 23610661pmc: 3626203doi: 10.1302/2046-3758.111.2000132google scholar: lookup
  6. Baek S-H, Kim S-Y. Pharmacologic treatment of osteoarthritis. J Korean Med Assoc 2013;56:1123–31.
    doi: 10.5124/jkma.2013.56.12.1123google scholar: lookup
  7. Thysen S, Luyten FP, Lories RJU. Targets, models and challenges in osteoarthritis research. Dis Models Mechanisms 2015;8:17–30.
    doi: 10.1242/dmm.016881google scholar: lookup
  8. Vrouwe JPM, Burggraaf J, Kloppenburg M, Stuurman FE. Challenges and opportunities of pharmacological interventions for osteoarthritis: A review of current clinical trials and developments. Osteoarthritis Cartilage Open 2021;3:100212.
    pubmed: 36474768pmc: 9718290doi: 10.1016/j.ocarto.2021.100212google scholar: lookup
  9. Loo SJQ, Wong NK. Advantages and challenges of stem cell therapy for osteoarthritis (Review). Biomed Rep 2021;15:67.
    pubmed: 34155451pmc: 8212446doi: 10.3892/br.2021.1443google scholar: lookup
  10. Correa D, Lietman SA. Articular cartilage repair: current needs, methods and research directions. Seminars in cell & developmental biology 2017: Elsevier.
  11. Ahern BJ, Parvizi J, Boston R, Schaer TP. Preclinical animal models in single site cartilage defect testing: a systematic review. Osteoarthritis Cartilage 2009;17:705–13.
    pubmed: 19101179doi: 10.1016/j.joca.2008.11.008google scholar: lookup
  12. Frisbie DD, Cross MW, McIlwraith CW. A comparative study of articular cartilage thickness in the stifle of animal species used in human pre-clinical studies compared to articular cartilage thickness in the human knee. Vet Comp Orthop Traumatol 2006;19:142–6.
    pubmed: 16971996doi: 10.1055/s-0038-1632990google scholar: lookup
  13. Malda J, Benders KE, Klein TJ, de Grauw JC, Kik MJ, Hutmacher DW. Comparative study of depth-dependent characteristics of equine and human osteochondral tissue from the medial and lateral femoral condyles. Osteoarthritis Cartilage 2012;20:1147–51.
    pubmed: 22781206doi: 10.1016/j.joca.2012.06.005google scholar: lookup
  14. McIlwraith CW. From arthroscopy to gene therapy--30 years of looking in joints. Proceedings of the annual convention 2005.
  15. Nelson BB, Kawcak CE, Barrett MF, McIlwraith CW, Grinstaff MW, Goodrich LR. Recent advances in articular cartilage evaluation using computed tomography and magnetic resonance imaging. Equine Vet J 2018;50:564–79.
    pubmed: 29344988doi: 10.1111/evj.12808google scholar: lookup
  16. Nelson BB, Goodrich LR, Barrett MF, Grinstaff MW, Kawcak CE. Use of contrast media in computed tomography and magnetic resonance imaging in horses: Techniques, adverse events and opportunities. Equine Vet J 2017;49:410–24.
    pubmed: 28407291doi: 10.1111/evj.12689google scholar: lookup
  17. Wu CL, Harasymowicz NS, Klimak MA, Collins KH, Guilak F. The role of macrophages in osteoarthritis and cartilage repair. Osteoarthritis Cartilage 2020;28:544–54.
    pubmed: 31926267pmc: 7214213doi: 10.1016/j.joca.2019.12.007google scholar: lookup
  18. McIlwraith CW. Traumatic arthritis and posttraumatic osteoarthritis in the horse. Joint disease in the horse Elsevier; 2016. p. 33–48.
  19. Frisbie DD, Johnson SA. Synovial joint biology and pathobiology. Equine surgery Elsevier; 2019. p. 1326–48.
  20. Estrada McDermott J, Pezzanite L, Goodrich L, Santangelo K, Chow L, Dow S. Role of Innate Immunity in Initiation and Progression of Osteoarthritis, with Emphasis on Horses. Animals 2021;11:3247.
    pubmed: 34827979pmc: 8614551doi: 10.3390/ani11113247google scholar: lookup
  21. McIlwraith CW, Fessler JF. Arthroscopy in the diagnosis of equine joint disease. J Am Vet Med Assoc 1978;172:263–8.
    pubmed: 621167
  22. Anderson DD, Chubinskaya S, Guilak F, Martin JA, Oegema TR, Olson SA. Post-traumatic osteoarthritis: improved understanding and opportunities for early intervention. J Orthop Res 2011;29:802–9.
    pubmed: 21520254pmc: 3082940doi: 10.1002/jor.21359google scholar: lookup
  23. Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone 2012;51:249–57.
    pubmed: 22387238pmc: 3372675doi: 10.1016/j.bone.2012.02.012google scholar: lookup
  24. Sutton S, Clutterbuck A, Harris P, Gent T, Freeman S, Foster N. The contribution of the synovium, synovial derived inflammatory cytokines and neuropeptides to the pathogenesis of osteoarthritis. Vet J 2009;179:10–24.
    pubmed: 17911037doi: 10.1016/j.tvjl.2007.08.013google scholar: lookup
  25. Cohen SB, Woolley JM, Chan W, Group AS. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J Rheumatol 2003;30:225–31.
    pubmed: 12563672
  26. Kary S, Burmester G. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis. Int J Clin Prac 2003;57:231–4.
    doi: 10.1111/j.1742-1241.2003.tb10469.xgoogle scholar: lookup
  27. Fleischmann R. Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology 2003;42:ii29–ii35.
    pubmed: 12817093doi: 10.1093/rheumatology/keg330google scholar: lookup
  28. Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T. Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double-blind, placebo-controlled study. Arthritis Care Res 2009;61:344–52.
    doi: 10.1002/art.24096google scholar: lookup
  29. Frisbie DD, Al-Sobayil F, Billinghurst RC, Kawcak CE, McIlwraith CW. Changes in synovial fluid and serum biomarkers with exercise and early osteoarthritis in horses. Osteoarthritis Cartilage 2008;16:1196–204.
    pubmed: 18442931doi: 10.1016/j.joca.2008.03.008google scholar: lookup
  30. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, McIlwraith CW. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002;9:12–20.
    pubmed: 11850718doi: 10.1038/sj.gt.3301608google scholar: lookup
  31. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003;10:2112–8.
    pubmed: 14625565doi: 10.1038/sj.gt.3302134google scholar: lookup
  32. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001;8:1248–54.
    pubmed: 11509958doi: 10.1038/sj.gt.3301514google scholar: lookup
  33. Goodrich LR, Grieger JC, Phillips JN, Werpy N, Krauss V, McIlwraith CW. scAAVIL-1ra Gene Therapy in an Equine Osteochondral Fragment Model of Osteoarthritis. Orthopaedic Research Society March 5; Orlando, FL 2016.
  34. Goodrich LR, Grieger JC, Phillips JN, Khan N, Gray SJ, McIlwraith CW. scAAVIL-1ra dosing trial in a large animal model and validation of long-term expression with repeat administration for osteoarthritis therapy. Gene Ther 2015;22:536–45.
    pubmed: 25902762pmc: 5567794doi: 10.1038/gt.2015.21google scholar: lookup
  35. Goodrich LR, Phillips JN, McIlwraith CW, Foti SB, Grieger JC, Gray SJ. Optimization of scAAVIL-1ra In Vitro and In Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis. Mol Ther Nucleic Acids 2013;2:e70.
    pubmed: 23385523pmc: 3586798doi: 10.1038/mtna.2012.61google scholar: lookup
  36. Hemphill D, McIlwraith C, Slayden R, Samulski R, Goodrich L. Adeno-associated virus gene therapy vector scAAVIGF-I for transduction of equine articular chondrocytes and RNA-seq analysis. Osteoarthritis Cartilage 2016;24:902–11.
    pubmed: 26706703doi: 10.1016/j.joca.2015.12.001google scholar: lookup
  37. Kay JD, Gouze E, Oligino TJ, Gouze JN, Watson RS, Levings PP. Intra-articular gene delivery and expression of interleukin-1Ra mediated by self-complementary adeno-associated virus. J Gene Med 2009;11:605–14.
    pubmed: 19384892pmc: 2876984doi: 10.1002/jgm.1334google scholar: lookup
  38. Watson Levings RS, Broome TA, Smith AD, Rice BL, Gibbs EP, Myara DA. Gene Therapy for Osteoarthritis: Pharmacokinetics of Intra-Articular Self-Complementary Adeno-Associated Virus Interleukin-1 Receptor Antagonist Delivery in an Equine Model. Hum Gene Ther Clin Dev 2018;29:90–100.
    pubmed: 29869540pmc: 6007808doi: 10.1089/humc.2017.142google scholar: lookup
  39. Watson Levings RS, Smith AD, Broome TA, Rice BL, Gibbs EP, Myara DA. Self-Complementary Adeno-Associated Virus-Mediated Interleukin-1 Receptor Antagonist Gene Delivery for the Treatment of Osteoarthritis: Test of Efficacy in an Equine Model. Hum Gene Ther Clin Dev 2018;29:101–12.
    pubmed: 29869535pmc: 6007806doi: 10.1089/humc.2017.143google scholar: lookup
  40. Watson RS, Broome TA, Levings PP, Rice BL, Kay JD, Smith AD. scAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints. Gene Ther 2013;20:670–7.
    pubmed: 23151520doi: 10.1038/gt.2012.81google scholar: lookup
  41. Andino LM, Conlon TJ, Porvasnik SL, Boye SL, Hauswirth WW, Lewin AS. Rapid, widespread transduction of the murine myocardium using self-complementary Adeno-associated virus. Genetic Vacc Ther 2007;5:1–6.
    doi: 10.1186/1479-0556-5-1google scholar: lookup
  42. Koilkonda RD, Chou TH, Porciatti V, Hauswirth WW, Guy J. Induction of rapid and highly efficient expression of the human ND4 complex I subunit in the mouse visual system by self-complementary adeno-associated virus. Arch Ophthalmol 2010;128:876–83.
    pubmed: 20625049pmc: 3431796doi: 10.1001/archophthalmol.2010.135google scholar: lookup
  43. Nathwani AC, Gray JT, Ng CY, Zhou J, Spence Y, Waddington SN. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 2006;107:2653–61.
    pubmed: 16322469pmc: 1895379doi: 10.1182/blood-2005-10-4035google scholar: lookup
  44. Goodrich LR, Brower-Toland BD, Warnick L, Robbins PD, Evans CH, Nixon AJ. Direct adenovirus-mediated IGF-I gene transduction of synovium induces persisting synovial fluid IGF-I ligand elevations. Gene Ther 2006;13:1253–62.
    pubmed: 16708081doi: 10.1038/sj.gt.3302757google scholar: lookup
  45. McIlwraith CW, Frisbie DD, Kawcak CE, Fuller CJ, Hurtig M, Cruz A. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the horse. Osteoarthritis Cartilage 2010;18:S93–105.
    pubmed: 20864027doi: 10.1016/j.joca.2010.05.031google scholar: lookup
  46. Committee AHS. Guide to veterinary services for horse shows. Lexington: American Association of Equine Practitioners. 1999.
  47. Seabaugh KA, Barrett MF, Rao S, McIlwraith CW, Frisbie DD. Examining the Effects of the Oral Supplement Biota orientalis in the Osteochondral Fragment-Exercise Model of Osteoarthritis in the Horse. Front Vet Sci 2022;9:858391.
    pubmed: 35720848pmc: 9198577doi: 10.3389/fvets.2022.858391google scholar: lookup
  48. King MR, Haussler KK, Kawcak CE, McIlwraith CW, Reiser RF 2nd, Frisbie DD. Biomechanical and histologic evaluation of the effects of underwater treadmill exercise on horses with experimentally induced osteoarthritis of the middle carpal joint. Am J Vet Res 2017;78:558–69.
    pubmed: 28441054doi: 10.2460/ajvr.78.5.558google scholar: lookup
  49. Simpson AJ, Cunningham GA, Porteous DJ, Haslett C, Sallenave JM. Regulation of adenovirus-mediated elafin transgene expression by bacterial lipopolysaccharide. Hum Gene Ther 2001;12:1395–406.
    pubmed: 11485631doi: 10.1089/104303401750298553google scholar: lookup
  50. Ramanathan M, Haskó G, Leibovich SJ. Analysis of signal transduction pathways in macrophages using expression vectors with CMV promoters: a cautionary tale. Inflammation 2005;29:94–102.
    pubmed: 16865543doi: 10.1007/s10753-006-9005-zgoogle scholar: lookup
  51. Bruening W, Giasson B, Mushynski W, Durham HD. Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter. Nucleic Acids Res 1998;26:486–9.
    pubmed: 9421504pmc: 147296doi: 10.1093/nar/26.2.486google scholar: lookup
  52. Svensson RU, Barnes JM, Rokhlin OW, Cohen MB, Henry MD. Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer Res 2007;67:10445–54.
    pubmed: 17974988doi: 10.1158/0008-5472.CAN-07-1955google scholar: lookup
  53. Kawabata A. Prostaglandin E2 and pain–an update. Biol Pharm Bull 2011;34:1170–3.
    pubmed: 21804201doi: 10.1248/bpb.34.1170google scholar: lookup
  54. Lin C-R, Amaya F, Barrett L, Wang H, Takada J, Samad TA. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 2006;319:1096–103.
    pubmed: 16966471doi: 10.1124/jpet.106.105569google scholar: lookup
  55. Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res 2007;68:290–6.
    pubmed: 17331019doi: 10.2460/ajvr.68.3.290google scholar: lookup
  56. Frisbie DD, McIlwraith CW. Evaluation of gene therapy as a treatment for equine traumatic arthritis and osteoarthritis. Clin Orthopaedics Related Res® 2000;379:S273–S87.
    doi: 10.1097/00003086-200010001-00037google scholar: lookup
  57. Payne KA, Lee HH, Haleem AM, Martins C, Yuan Z, Qiao C. Single intra-articular injection of adeno-associated virus results in stable and controllable in vivo transgene expression in normal rat knees. Osteoarthritis Cartilage 2011;19:1058–65.
    pubmed: 21571082pmc: 3139006doi: 10.1016/j.joca.2011.04.009google scholar: lookup
  58. Lee HH, O’Malley MJ, Friel NA, Payne KA, Qiao C, Xiao X. Persistence, localization, and external control of transgene expression after single injection of adeno-associated virus into injured joints. Hum Gene Ther 2013;24:457–66.
    pubmed: 23496155pmc: 3631018doi: 10.1089/hum.2012.118google scholar: lookup

Citations

This article has been cited 1 times.
  1. Kearney CM, Korthagen NM, Plomp SGM, Labberté MC, de Grauw JC, van Weeren PR, Brama PAJ. A Translational Model for Repeated Episodes of Joint Inflammation: Welfare, Clinical and Synovial Fluid Biomarker Assessment.. Animals (Basel) 2023 Oct 12;13(20).
    doi: 10.3390/ani13203190pubmed: 37893914google scholar: lookup
Subscribe to our newsletter
Join 99,383 horse owners like you who receive our email updates on horse health and nutrition.